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Functional Stability of HIV-1 Envelope
Trimer Affects Accessibility to Broadly
Neutralizing Antibodies at Its Apex
Syna Kuriakose Gift,* Daniel P. Leaman, Lei Zhang, Arthur S. Kim,*
Michael B. Zwick
Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, California, USA
ABSTRACT The trimeric envelope glycoprotein spike (Env) of HIV-1 is the target of
vaccine development to elicit broadly neutralizing antibodies (bnAbs). Env trimer in-
stability and heterogeneity in principle make subunit interfaces inconsistent targets
for the immune response. Here, we investigate how functional stability of Env re-
lates to neutralization sensitivity to V2 bnAbs and V3 crown antibodies that engage
subunit interfaces upon binding to unliganded Env. Env heterogeneity was inferred
when antibodies neutralized a mutant Env with a plateau of less than 100% neutral-
ization. A statistically signiﬁcant correlation was found between the stability of mu-
tant Envs and the MPN of V2 bnAb, PG9, as well as an inverse correlation between
stability of Env and neutralization by V3 crown antibody, 447-52D. A number of Env-
stabilizing mutations and V2 bnAb-enhancing mutations were identiﬁed in Env, but
they did not always overlap, indicating distinct requirements of functional stabiliza-
tion versus antibody recognition. Blocking complex glycosylation of Env affected V2
bnAb recognition, as previously described, but also notably increased functional sta-
bility of Env. This study shows how instability and heterogeneity affect antibody sen-
sitivity of HIV-1 Env, which is relevant to vaccine design involving its dynamic apex.
IMPORTANCE The Env trimer is the only viral protein on the surface of HIV-1 and is
the target of neutralizing antibodies that reduce viral infectivity. Quaternary epitopes
at the apex of the spike are recognized by some of the most potent and broadly
neutralizing antibodies to date. Being that their glycan-protein hybrid epitopes are
at subunit interfaces, the resulting heterogeneity can lead to partial neutralization.
Here, we screened for mutations in Env that allowed for complete neutralization by
the bnAbs. We found that when mutations outside V2 increased V2 bnAb recogni-
tion, they often also increased Env stability-of-function and decreased binding by
narrowly neutralizing antibodies to the V3 crown. Three mutations together in-
creased neutralization by V2 bnAb and eliminated binding by V3 crown antibodies.
These results may aid the design of immunogens that elicit antibodies to the trimer
apex.
KEYWORDS envelope, gp120, gp41, human immunodeﬁciency virus, neutralizing
antibodies, protein stability, vaccines
Amajor goal of HIV-1 vaccine design is to elicit broadly neutralizing antibodies(bnAbs) that can protect against infection (1–3). The HIV-1 envelope glycoprotein
(Env) spike tends to elicit B cell responses to variable regions and not to more
conserved sites that are relatively hindered by adjacent glycosylation (2, 4–6). “Well-
ordered” soluble Env trimers (e.g., SOSIP and NFL gp140s) have been developed to
mimic the Env spike, which is comprised of three surface subunits (gp120) and three
transmembrane subunits (gp41) (3, 7–10). These soluble trimers display desirable
quaternary epitopes of various bnAbs, but how well they mimic native epitopes is not
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fully understood. In principle at least, the formation (and disruption) of quaternary
epitopes relate to the stability of the Env trimer. Determining the potency, afﬁnity and
completeness of binding of antibodies to native Env, particularly to the V2 and V3
domains at its apex, might be crucial for vaccine design, since some studies have
associated these regions with vaccine protection (11–13).
bnAbs against V2 derive from HIV-1-infected donors and are sensitive to Env trimeric
structure; these bnAbs include PG9 and PG16 (14), PGT141-145 (15), VRC256.01-08 (16),
and PGDM1400 (17), the latter being a potent variant in the PGT145 lineage. V2 bnAbs
bind one-per-spike to a single -strand “C” and N-linked glycan at position 160 while
avoiding adjacent variability in V1V2 (4, 14, 15, 17–24). V2 bnAbs typically have long
tyrosine-sulfated CDR H3s that interact with positively charged lysine residues in the C
strand, including K168, K169, and K171 (21, 25, 26), but glycans proximal to N160 can
also inﬂuence binding and neutralization (27, 28). V2 bnAb CH01 neutralizes a modest
number (i.e., 48%) of tier 2 isolates and shows preference for trimmed man5 glycan at
positions 156 and 160 on V2 (22). Kifunensine treatment of producer cells generates
Env with untrimmed glycans (e.g., man9) that typically abrogates binding and neutral-
ization by V2 bnAbs due to poor accommodation of man9 in their antigen-combining
sites (15, 28–30).
Beneath V2 on Env lays V3, with its crown pointing inward toward the trifold axis of
the spike (8). The exposure of the V3 crown on the trimer depends directly on its
interaction with adjacent residues in gp120 (31). The crown is accessible to “tier 1”
neutralizing antibodies, including 447-52D, F425-B4e8, and 19b, which typically cannot
neutralize “tier 2” primary isolates due in part to masking of V3 by V1V2 on the resting
spike (32). V3 extends outward from the crown to a conserved and exposed glycan at
N332, which is a target of highly potent bnAbs including PGT121-122, PGT126, and
PGT128 (15, 33, 34). Env trimers that occlude the V3 crown but stabilize the N332
supersite are of interest as immunogens (35–37).
Heterogeneity in Env is not uncommon (5). Glycosylation seems to be the dominant
cause, which on V2 and gp41 can be relatively complex and variable (4, 38–41), but
other factors that affect protein folding might also contribute. Env microheterogeneity
may cause nonsigmoidal inhibition curves with HIV-1 and less than 100% maximum
percent neutralization (MPN). Atypical neutralization curves have been associated
mostly with bnAbs to V2, membrane-proximal external region (MPER) and the gp41
interface (5, 42, 43). Because antibody binding to these regions perturbs trimer sym-
metry (24, 43), preexisting heterogeneity in Env may affect antibody binding on a
molecule-by-molecule basis by facilitating or resisting formation of the antibody-trimer
complex.
We reported previously on a clade B Env trimer that was stabilized using directed
evolution (44). We discovered that the stabilized Env, termed Comb-mut, was incom-
pletely neutralized by V2 antibodies PG9 and PG16 and showed a tier 2-like resistance
to narrow CD4 binding site (CD4bs) antibodies. In contrast, its labile Env counterpart,
ADA, was relatively neutralization sensitive (tier 1-like). To determine the relationship
between stability, heterogeneity and neutralization sensitivity at the apex of Env, we
screened mutants of ADA and Comb-mut in assays for functional stability of Env and
MPN of PG9, and a correlation was found between the two traits. Env stability of
function also correlated inversely with the neutralization by V3 crown antibodies. A
number of trimer stabilizing mutants were identiﬁed, and select mutant spikes showed
relatively homogeneous neutralization by V2 bnAbs and relative occlusion of the V3
crown. The results accord with structural models of Env and inform the design of
homogeneous HIV-1 trimer-based vaccines.
RESULTS
Neutralization of HIV-1 Env mutants by PG9 and V3 antibodies. Comb-mut is a
mutant of HIV-1 ADA containing eight stabilizing mutations in Env (i.e., I535M, L543Q,
K574R, H625N, T626M, S649A, N142S, and an N139/I140 deletion) that evolved during
adaption of ADA to treatment with heat and GuHCl (44). Comb-mut was shown
Gift et al. Journal of Virology
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previously to be more thermostable than a broad panel of tier 1 and tier 2 isolates (44,
45). In neutralization assays with PG9 and PG16, Comb-mut showed higher MPN values
compared to ADA, but both viruses remained partially neutralized (i.e., 92 and 94% for
Comb-mut versus 85 and 87% for ADA, respectively; Fig. 1A). The slopes of neutraliza-
tion curves of PG9 and PG16 against Comb-mut were also steeper than with ADA,
which suggests that Comb-mut trimers may be more homogeneous and uniformly
recognized. In neutralization assays with V3 antibodies 447-52D and F425-B4e8, as
well as the CD4bs “non-bnAbs” b6 and F105, we found that ADA was neutralized with
shallow dose-response curves, although 100% neutralization was reached at high
concentrations of V3 antibodies (Fig. 1B). Comb-mut was resistant to F105, b6, and V3
crown antibodies 19b and 39F (data not shown) but was modestly sensitive to
F425-B4e8 and 447-52D. However, 447-52D neutralized ADA (50% inhibitory concen-
tration [IC50]  0.05 g/ml) 100-fold more potently than Comb-mut. The neutraliza-
tion curves with Comb-mut had the expected sigmoidal shape but were shallow with
ADA (Hill slopes of 0.87 and 0.18, respectively). These results indicated that on Comb-
mut epitopes of most non-bnAbs were relatively occluded and V2 bnAb epitopes were
retained. We sought to investigate how V3 crown exposure and V2 heterogeneity in
Comb-mut and ADA relate to functional stability of Env and to identify functional Env
with improved V2 bnAb recognition and with V3 occluded.
Mutations that enhance neutralization of HIV-1 by PG9. To gain insight into V2
exposure on ADA and Comb-mut, we generated a mutant Env panel to be screened for
sensitivity to PG9. Mutations in or near to the PG9-binding site were chosen in part
based on sequence alignment of ADA, Env consensus M (ConS), as well as clade A and
C stable Env trimers, BG505 and 16055, respectively, the latter of which exhibit 100%
MPNs against PG9 and PG16 (Fig. 2). We also tested a variety of mutations outside of
V1V2, including N-glycosylation knockouts, mutations that caused resistance to entry
inhibitors PF-68742 (46) and 5P12-RANTES (47), as well as others which had been
described or suspected to affect Env trimerization, as cited in Table 1 and discussed
further below.
FIG 1 Neutralization of ADA and Comb-mut by V2 bnAbs, V3 crown antibodies, and CD4bs non-bnAbs. HIV-1 ADA
and Comb-mut virions were tested in neutralization assays against the V2 bnAbs PG9 and PG16 (A) and the V3
crown antibodies 447-52D and F425-B4e8 and the CD4 binding site (CD4bs) non-bnAbs b6 and F105 (B). In panel
A, the maximum percent neutralization (MPN) for each virus-antibody pair is noted.
HIV Envelope Stability and Apex Neutralization Journal of Virology
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Mutants were screened for MPN with PG9 at a concentration of 5 g/ml, which is
well into the plateau of the dose-response curve with both ADA and Comb-mut. Of the
36 mutants tested, 17 substitutions signiﬁcantly enhanced neutralization of ADA by
PG9, including eight outside V1V2 (Fig. 3 and Table 1). Fourteen substitutions had little
effect, and another ﬁve diminished PG9 MPN (i.e., N130Q, K170Q, A174S, T200A, and
I309M). Substitutions in ADA that enhanced PG9 neutralization were also introduced
into Comb-mut, along with some mutations that we speculated might affect trimer
stability based on analysis of the crystal structure of the stable BG505 SOSIP trimer (8).
Of the substitutions that enhanced the MPN of PG9 in ADA, only I165L and V169K did
so with Comb-mut; however, a trend toward a higher MPN was observed with Comb-
mut S164E and D187N (Fig. 3; Table 1). Hence, only substitutions in V2, near residues
166 to 176 of the C strand, enhanced PG9 neutralization (i.e., the MPN) of both labile
and stable Env trimers, i.e., ADA and Comb-mut.
Mutations I165L and V169K were combined to produce the double mutants ADA-LK
and CM-LK. Combining the two substitutions enabled 100% neutralization of CM-LK by
PG9 and PG16 with a reduction in IC50s by 9- and 4-fold, respectively (Fig. 4 and Table
2). Neutralization curves of PG9 and PG16 increased in slope from parental virus to the
double mutant (i.e., slopes of ADA and Comb-mut increased from 0.5 and 0.8 to 1.1 and
1.3 for the LK mutants, respectively). Thus, the LK mutation enhanced both potency and
completeness of PG9/PG16 neutralization, suggesting that the V2 supersite became
more accessible and homogeneous throughout the virion population.
Stability of ADA mutants correlates with PG9 neutralization (MPN). To deter-
mine whether substitutions that affect PG9 neutralization also affect Env stability, we
turned to a stability-of-function assay we described previously that determines the
temperature at which infectivity of HIV-1 decreases by 90% in 1 h involving an Env of
interest pseudotyped on a constant viral backbone (i.e., a T90 assay) (45). Notably, of
the 16 mutations discussed above to enhance the MPN of PG9, 6 were also signiﬁcantly
stabilizing for ADA (i.e., T90 increased to 45.3 to 47.3°C from 42.7°C [P  0.05]), while
several others trended toward stabilization (Table 1). The six mutations that stabilized
ADA and enhanced PG9 MPN were in V1 (N136S and S143D), V3 (N302Y, R315Q, and
A316T), and the gp41 disulﬁde loop region (T605P). These mutations also tended to
FIG 2 Alignment of V1V2 and V3 sequences. The V1V2 (A) and V3 (B) amino acid sequences of the group M consensus (ConS), ADA, Comb-mut,
BG505, and 16055 were aligned using DNASTAR Lasergene ClustalW with an HxB2 numbering scheme. Highlighted in gray are residues that differ
from ConS. Residues in red indicate N-linked glycosylation sites at N156 and N160. Highlighted in yellow are positions 165, 169, and 315; the
former two were mutated I165L/V169K to generate ADA-LK and CM-LK, and the latter was mutated R315Q to eliminate neutralization by V3 crown
antibodies. Amino acids represented in green are 50% conserved among all isolates, and those boxed in red are 50% conserved among
subtype B (hiv.lanl.org). The beta-sheet structure and labeling are indicated by black arrows, based on data published by McLellan et al. for V2
(21) and Huang et al. for V3 (87).
Gift et al. Journal of Virology
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show higher MPN values of PG9 against ADA (Table 1). Notably, when all mutations
were analyzed, a statistically signiﬁcant positive correlation (P  0.0004) was observed
between T90 and MPN of PG9 (Fig. 5A). No correlation was observed between T90 and
PG9 IC50 (P  0.3244; data not shown). Altogether, a total of 14 mutations stabilized
ADA while showing positive effects on PG9 neutralization.
FIG 3 Neutralization (MPN) of mutant Envs of HIV-1 ADA and Comb-mut by PG9. Substitutions were
introduced into ADA pseudovirus and mutants were tested for sensitivity to PG9 neutralization at a
constant concentration of 5 g/ml. A subset of substitutions that showed a signiﬁcant increase in MPN was
then similarly tested in a Comb-mut Env background. Certain mutations that were predicted by structural
analysis to potentially affect V2 and V3 antibody neutralization were also tested in Comb-mut but not ADA.
Mutations that were not tested in a given background are labeled “nd” (not determined) or “ni” (not
infectious). “N186-188” represents the triple mutant N186G/D187S/N188S. The red and green dashed lines
indicate MPNs for wild-type ADA and Comb-mut, respectively. Red dots indicate mutants that show
enhanced PG9 neutralization relative to wild-type ADA, green dots indicate enhanced PG9 neutralization
of both ADA and Comb-mut. Each bar represents an average of biological triplicate values.
FIG 4 Comb-mut containing V2 substitutions I165L and V169K is neutralized completely and efﬁciently by PG9 and PG16. ADA (A) and
Comb-mut (B) parental pseudoviruses (black circles), as well as I165L V169K double mutants (red squares), were assayed for neutralization
against PG9 (top panels) and PG16 (bottom panels). Experiments were performed in triplicate.
Gift et al. Journal of Virology
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The functional stability (T90) of Comb-mut was determined to be at the maximum
limit possible with the infectivity-based assay (i.e., T9050°C), since components of the
viral backbone inactivate around this temperature (44, 45). All of the Comb-mut
mutants were similarly at the maximum T90 value for this assay and so are most likely
TABLE 2 Substitutions I165L and V169K enhance neutralization of HIV-1 ADA and Comb-
mut by PG9 and PG16
Virus
PG9 PG16
IC50 (g/ml) MPN (%) Slope IC50 (g/ml) MPN (%) Slope
ADA WT 0.272 88 0.59 0.026 94 0.56
ADA I165L 0.067 96 0.59 0.010 98 0.63
ADA V169K 0.016 99 0.49 0.006 99 0.49
ADA-LK 0.034 97 1.10 0.037 96 0.79
Comb-mut WT 0.268 92 0.89 0.099 92 0.80
Comb-mut I165L 0.158 99 0.79 0.048 98 1.26
Comb-mut V169K 0.037 100 0.83 0.017 98 1.98
CM-LK 0.030 100 1.38 0.022 100 1.33
FIG 5 Stability of Env correlates with enhanced MPN of PG9 and decreased neutralization by 447-52D.
(A) Mutants of ADA were tested for thermostability and neutralization by PG9. T90 values are plotted
against the percent neutralization at 5 g/ml of PG9. A statistically signiﬁcant relationship was observed
between increased Env stability and an increase in PG9 neutralization. (B) Infectivity decay at 37°C of
ADA, Comb-mut, and CM-LK. The results of a representative experiment performed in triplicate are
shown, and the error bars represent the standard deviations. (C) Physical thermostability of Comb-mut
and CM-LK Env trimers. BN-PAGE Western blot analysis of trimeric Envs solubilized from heat-treated
virus shows that I165L/V169K do not change the trimer stability of Comb-mut.
HIV Envelope Stability and Apex Neutralization Journal of Virology
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comparable in stability to Comb-mut. Because I165L and V169K improved PG9/PG16
neutralization of ADA and Comb-mut without affecting the T90, we further tested
Comb-mut and its mutant CM-LK for infectivity decay at 37°C, as well as its physical
trimer stability. (We note that Comb-mut trimers previously showed higher physical
stability than ADA in a temperature gradient Blue Native-PAGE [BN-PAGE] assay by
12°C [44].) No differences between Comb-mut and CM-LK were observed in the
half-life of infectivity decay at 37°C or in the integrity of heat-treated Env trimers on
BN-PAGE (Fig. 5B and C). We conclude that I165L and V169K enhance PG9/PG16
neutralization without altering Env trimer stability and hence are distinct from the
many non-V2 mutations in which Env ADA stability and MPN of PG9 appear to be
linked.
Mutations I165L and V169K enhance neutralization of ADA by several V2
bnAbs. We assayed ADA-LK and CM-LK for neutralization by additional V2 bnAbs
including, PGT145 (15), CH01 (22), VRC26.08 (16), and PGDM1400 (17). As with PG9 and
PG16, PGDM1400 neutralized ADA-LK and CM-LK with IC50s lower than parental viruses
and with 100% neutralization, which is consistent with the superior breadth of
PGDM1400 (Fig. 6A) (17). ADA and Comb-mut were resistant to VRC26.08 and CH01, but
the LK substitution made these viruses highly sensitive to VRC26.08 and partially
sensitive to CH01 (MPN of 40%), which lends support to the reported dependence of
these bnAbs on K169 (48).
PGT145 was an exception, however, since the LK mutation caused IC50s to increase
5- to 10-fold and MPNs to decrease from 100% to 82 to 91% (Fig. 6A). The effect was
localized because ADA-LK and CM-LK showed no change in sensitivity to non-V2 bnAbs,
including those against the CD4bs, N332 glycan, and MPER of gp41 (Fig. 6A; data not
shown). Further analysis showed that V169K was largely responsible for the observed
changes in PGT145 and VRC26.08 neutralization (Fig. 6B).
We also compared the neutralization sensitivity of ADA, ADA-LK, Comb-mut, and
CM-LK toward gp120-gp41 interface bnAbs PGT151, 35O22, and 3BC176, since these
bnAbs are known to only partially neutralize many isolates (49–51). Interestingly,
Comb-mut was much more completely and potently neutralized by all three Abs than
ADA (Fig. 6C). This effect could be the result of a shift in a gp41 glycan at the
gp120-gp41 interface from N624 in ADA to N625 in Comb-mut (44). 35O22 depends on
the glycan at N625 and, whereas an N625 glycan-knockout does not strongly affect
neutralization by either PGT151 or 3BC176, the 624/625 glycan shift may perhaps alter
their epitopes given the extreme proximity of these residue positions (49–51). The LK
mutations did not signiﬁcantly improve the MPN of the interface bnAbs against
Comb-mut, but Comb-mut is already neutralized 100% by PGT151 and 96% by 35O22.
However, PGT151 neutralization of ADA was improved by these mutations (ADA 23%
MPN; ADA-LK 55% MPN), which suggests that these mutations generally increase the
homogeneity of Env even at distal sites.
We further tested the sensitivity of ADA, ADA-LK, Comb-mut, and CM-LK to soluble
CD4 (sCD4) as another measure of the effect of I165L and V169K on Env stability, since
resistance to sCD4 has been associated with greater Env stability (44, 52). As previously
reported (44), Comb-mut was more resistant to sCD4 than ADA by 70-fold (Fig. 6C).
The LK mutations had little effect on sCD4 inhibition of Comb-mut, supporting the
BN-PAGE data showing that Comb-mut and CM-LK are roughly equal in stability (Fig.
5C). I165L and V169K increased sensitivity of ADA to sCD4 by 5-fold, which is a
somewhat speciﬁc effect since thermostability was unaffected by these two mutations
in ADA (Table 1).
Blocking complex glycosylation alters V2 bnAb neutralization of ADA/Comb-
mut mutants. Blocking the trimming of high-mannose on N-linked glycosylation of
HIV-1 Env affects neutralization by V2 bnAbs (4). We investigated this aspect of glycan
processing on neutralization of ADA/Comb-mut and cognate LK mutants. Pseudotyped
viruses were produced under different conditions to generate trimmed N-linked gly-
cans: (i) in GnTI/ (293S) cells that produce Man5-9GlcNAc2 (4), (ii) in 293T cells
treated with kifunensine that generate Man9GlcNAc2 (53), or (iii) in cells treated with
Gift et al. Journal of Virology
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swainsonine that results in GlcNAcMan5GlcNAc2 with possible hybrid glycans on the
third arm (4). Kifunensine-treated viruses were resistant to all of the V2 bnAbs tested,
a ﬁnding consistent with prior studies (data not shown) (4, 17). However, production of
Env in the presence of swainsonine or in 293S cells had various effects on different
Ab-Env combinations. First, swainsonine reduced the MPN of PGT145 against the LK
mutants and not wild-type viruses; 293S cell production did not have this effect (Fig. 7A
FIG 6 Neutralization of Comb-mut and CM-LK by V2 antibodies. (A) Comb-mut and CM-LK pseudotyped
viruses were tested against various V2 bnAbs, as well as control antibodies PGT128 and VRC01. (B) The
MPN of V2 bnAbs is shown against Comb-mut, CM-LK, and the constituent mutations of CM-LK, I165L
and V169K. (C) ADA, ADA-LK, Comb-mut, and CM-LK pseudotyped viruses were tested in TZM-bl
neutralization assays against gp120-gp41 interface bnAbs and the soluble form of the HIV-1 receptor,
CD4. Data shown are from a representative experiment performed in triplicate, and error bars represent
the standard deviations from the mean.
HIV Envelope Stability and Apex Neutralization Journal of Virology
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to D; Table 3). Second, producing virus in 293S cells increased the MPN of CH01 in all
cases, reaching 100% against CM-LK. Third, VRC26.08 neutralization was abrogated
when virus was produced in 293S cells. Lastly, swainsonine treatment increased sen-
sitivity of ADA-LK and CM-LK to VRC26.08 without increasing MPNs. The latter three
ﬁndings suggest that CH01 binds better to terminal mannose glycans, whereas
VRC26.08 prefers complex glycosylation.
The glycan contacts with V2 bnAbs in structural models mainly involve N160, with
N156 supplying secondary contacts (21, 28–30, 54). We made knockouts of these
glycans in Comb-mut and CM-LK and assayed virus sensitivity to the V2 bnAbs used
above. As expected, N160A abolished neutralization by all antibodies (data not shown).
N156S had little effect on PGT145 neutralization of Comb-mut and diminished the PG9
IC50 5-fold (Fig. 7C and D; Table 3). In contrast, N156S in the CM-LK background reduced
FIG 7 Neutralization properties of glycosylation-modiﬁed HIV-1 ADA, ADA-LK, Comb-mut, and CM-LK Env
by V2 bnAbs. ADA (A), ADA-LK (B), Comb-mut (C), and CM-LK (D) pseudotyped viruses were generated in
293T cells, in 293S cells, or in the presence of swainsonine. Virions of Comb-mut and CM-LK that had the
N156S mutation, which eliminates the glycosylation site at this position, were also generated in 293T cells.
Viruses were tested in neutralization assays against V2 bnAbs PG9, PGT145, CH01, and VRC26.08. The MPN
ﬁndings are shown in panels A to D. (E) The stability of ADA wild-type and ADA-LK virion Envs produced
in 293T or 293S cells or in the presence of kifunensine or swainsonine was tested in a T90 assay. A
statistically signiﬁcant increase in the functional stability of Env was found with each treatment relative to
producing virus in 293T cells. The statistical signiﬁcance was determined using a paired two-tailed t test. (F)
Six different viruses from different clades were produced with or without the addition of kifunensine, and
the functional stability was tested in the T90 assay.
Gift et al. Journal of Virology
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the PG9 IC50 80-fold, abrogated neutralization by PGT145, and severely reduced
neutralization by both CH01 and VRC26.08. We assume that the glycan knockout at
N156 alters glycosylation at N160 or its packing with the B and C strands as a part of
the V2 epitope (54), thereby increasing the dependence of all of the V2 bnAbs on the
glycan at N156.
Preventing complex glycosylation increases thermostability of Env. We wished
to determine whether blocking complex glycosylation affected the functional stability
of Env. Thus, ADA and ADA-LK glycosylation modiﬁed variants were assessed for
thermostability using the heat gradient (T90) assay. Kif-, swain-, and GnTI/ cell-
treated viruses all showed enhanced T90s that went from42°C to 47 to 51°C (Fig. 7E).
Hence, blocking complex glycosylation and/or mannose trimming generally increased
the thermostability of ADA. The Comb-mut variants showed maximum T90 values
irrespective of the glycosylation modiﬁcations, suggesting that the stable Comb-mut
trimer is at least not destabilized by changes in glycosylation. To determine whether
blocking complex glycosylation and mannose trimming is stabilizing for other Envs, a
panel of pseudotyped viruses of modest stability (i.e., T90s 43 to 46°C) was similarly
produced in the presence or absence of kifunensine and tested for thermostability. Five
of ﬁve viruses showed increased T90s when produced in the presence of kifunensine
(P  0.0003). Taken together, our data show that complex glycosylation is generally
unfavorable for functional stability, at least with moderately stable Envs.
PG9 and PGT145 together fully neutralize mixed Env trimers. Incomplete neu-
tralization by a V2 bnAb might arise from variation in glycosylation or folding that
occludes the three potential binding sites on the trimer. However, it is unclear whether
or how adjacent protomers inﬂuence this resistance. We performed a mixed trimer
experiment in which Env plasmids of Comb-mut and CM-LK—which show partial
resistance to PG9 and PGT145, respectively—were mixed 1:1 prior to preparing pseu-
dotyped virus. Neutralization assays were performed using PG9, PGT145, and a cocktail
of the two bnAbs. We found that mixed-trimer virus was partially resistant to single
bnAbs and fully neutralized by the double bnAb cocktail (Table 4). These results
support a model in which mixing protomers does not cause resistance to both bnAbs
that would have indicated supraheterogeneity in mixed subunit interfaces.
TABLE 3 Neutralization of glycosylation-modiﬁed pseudotyped virus by V2 bnAbs
nAb
293T 293S Swainsonine N156 N160
IC50 (g/ml) MPN (%) IC50 (g/ml) MPN (%) IC50 (g/ml) MPN (%) IC50 (g/ml) MPN (%) IC50 (g/ml) MPN (%)
ADA
PG9 0.27 88 0.35 94 0.12 90 NDa ND ND ND
PGT145 0.10 99 0.08 100 0.02 100 ND ND ND ND
CH01 25 40 0.83 87 25 48 ND ND ND ND
VRC26.08 25 3 25 22 25 3 ND ND ND ND
ADA-LK
PG9 0.03 97 0.78 98 0.40 98 ND ND ND ND
PGT145 0.39 91 1.31 81 8.02 65 ND ND ND ND
CH01 20.10 52 1.82 92 13.40 56 ND ND ND ND
VRC26.08 0.52 89 25 16 0.05 92 ND ND ND ND
Comb-mut
PG9 0.27 92 0.23 98 0.08 100 1.39 65 25 16
PGT145 0.08 100 0.07 100 0.05 100 0.02 96 25 15
CH01 25 29 0.45 98 2.77 71 25 20 25 19
VRC26.08 25 9 25 29 25 7 25 6 25 16
CM-LK
PG9 0.03 100 0.19 100 0.38 100 2.40 69 25 0
PGT145 1.00 82 0.76 80 25 34 25 22 25 0
CH01 7.58 57 0.34 100 7.99 66 25 26 25 0
VRC26.08 0.17 96 25 16 0.03 96 25 55 25 36
aND, not determined.
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V2 bnAbs with higher MPNs bind to a greater proportion of Env trimers.
Incomplete neutralization of virus by V2 bnAbs presumably results from a failure to
recognize a subpopulation of Env. To investigate, we coincubated V2 bnAbs with
Comb-mut and CM-LK virions, detergent solubilized the Env-bnAb complexes, and
visualized the complexes using a gel mobility shift assay employing BN-PAGE and
Western blotting. Several observations were notable. First, PG9 and PG16 completely
shifted the band corresponding to CM-LK trimers, but with Comb-mut a fraction of
trimers remained unshifted, which suggests that I165L/V169K overcomes microhetero-
geneity in Comb-mut to allow binding to all of its spikes (Fig. 8A). Second and
surprisingly, PGT145 and PGDM1400 did not fully shift the Comb-mut trimer band
despite achieving 100% MPNs and totally failed to shift CM-LK spikes. Gel mobility shifts
were also absent with VRC26.08 and CH01 against both viruses, even though they
partially neutralized CM-LK.
TABLE 4 HIV-1 with mixed Comb-mut/CM-LK Env trimers is neutralized completely by
combining PG9 and PGT145
Virus
PG9 PGT145 PG9PGT145
IC50 (g/ml) MPN (%) IC50 (g/ml) MPN (%) IC50 (g/ml) MPN (%)
Comb-mut 0.27 92 0.08 100 0.01 100
CM-LK 0.03 100 1.00 82 0.03 100
Comb-mut/CM-LK 0.09 98 0.06 97 0.07 100
FIG 8 BN-PAGE gel mobility shift of Comb-mut and CM-LK trimeric Env in the presence of various bnAbs.
(A) Comb-mut and CM-LK virions, displaying 95% cleaved Env, were incubated in the presence of the
IgGs speciﬁed (25 g/ml) and analyzed using BN-PAGE Western blot. Binding of an antibody causes the
Env trimer to run more slowly on the gel, thus shifting the band upward on the blot. 2G12 and DEN3
were used as positive- and negative-control antibodies, respectively. (B) Virion-antibody complexes were
ﬁxed using the chemical cross-linker BS3—after antibody binding but before adding detergent—to
prevent antibodies from falling off during the gel run. (C) Comb-mut and CM-LK virions were incubated
with 447-52D or F425-B4e8 IgGs that bind to V3, or control IgG 2G12, and then Env trimers were
solubilized using detergent and analyzed using a BN-PAGE Western blot.
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We suspected that, where there was a lack of correlation between gel mobility
shift and neutralization, bnAbs might have dissociated from Env, either following
detergent treatment or during electrophoresis. To test this hypothesis, we cross-
linked bnAb-virion complexes prior to adding detergent (37). Cross-linking increased
the apparent occupancy of V2 bnAbs on Env spikes in almost all cases in which V2
bnAbs neutralized and gel shifts were inefﬁcient (Fig. 8B). This is most prominently seen
with PGDM1400 and VRC26.08 against CM-LK, perhaps because these antibodies are
particularly sensitive to the quaternary state of Env and therefore might dissociate from
the spikes most easily upon detergent treatment (16, 17). CH01 failed to produce a shift;
however, CH01 only neutralizes CM-LK with an MPN of40%, so occupancy appears to
be transient and limited with this antibody. Taken together, the BN-PAGE data broadly
align with the neutralization results and imply that substitution LK alters the antibody-
binding site to make the virus/Env population uniformly recognizable to PG9, PG16,
and VRC26.08, but not to PGT145.
V3 crown neutralization correlates inversely with stability of ADA. The spike of
Comb-mut is more physically thermostable than a variety of tier 1 and tier 2 primary isolates
(44, 45). Comb-mut was modestly sensitive to V3 crown antibodies 447-52D and F425-B4e8
(Fig. 1B; IC50s 10 g/ml), which was surprising since Comb-mut is resistant to other V3
crown antibodies, CD4bs antibodies b6 and F105, and CD4i antibodies 17b and X5. We
screened various ADA mutants against 447-52D and found a signiﬁcant inverse correlation
between the T90 and the IC50 values of 447-52D (P  0.0001; Fig. 9A). There was also a
positive relationship between decreased 447-52D potency and the increased MPN of PG9,
and this relationship attained statistical signiﬁcance if V2 mutations in the PG9 interface
were excluded (Fig. 9B). Taken together, we conclude that Env trimer stabilization tends to
reduce exposure of V3 at the apex of the spike.
Antibodies to the V3 crown can neutralize HIV either by binding to Env prior to
attachment with CD4 or postattachment (55). We tested the ability of 447-52D and
F425-B4e8 to bind to unliganded trimers on Comb-mut and CM-LK virions using a
BN-PAGE gel mobility shift assay (44, 56). F425-B4e8 showed no binding or shifting of
the Env trimer on BN-PAGE (Fig. 8C). 447-52D did cause the trimer to “trail” upwards
slightly on the gel; however, this was not a clean shift of the trimer as with control
antibody 2G12. We infer from these results that 447-52D interacts only very weakly or
transiently with Comb-mut and CM-LK unliganded trimers, if at all, and neutralizes
these viruses when Env is in another conformation (e.g., post-CD4 engagement).
Mutation of Env to further attenuate V3 crown recognition. Given the possible
relevance of V3 crown exposure to vaccine design, we assessed the neutralization
sensitivity of CM-LK—the mutant most fully neutralized by the majority of V2 bnAbs—
using V3 crown antibodies 447-52D and F425-B4e8. Similar to Comb-mut, it was
modestly sensitive to these antibodies (Fig. 9C). 19b and 39F and coreceptor-binding
site antibody 17b showed no capacity to neutralize CM-LK (data not shown). We
screened 22 mutants of Comb-mut for neutralization by V3 crown antibodies and V2
bnAbs. Of the mutations we tested, only R315Q, which converts the V3 crown from the
consensus motif of clade B to that of clades A and C (i.e., GPGR¡GPGQ) abrogated
neutralization by both 447-52D and F425-B4e8 (Fig. 9C; data not shown) (57). Notably,
R315Q also increased the MPN of PG9 against ADA and stabilized ADA with a T90
increasing from 42.7 to 45.6°C (Fig. 3; Table 1). Although the mechanism of trimer
stabilization by R315Q is not obvious, in the crystal structure of BG505 SOSIP, position
315 is buried in the trimer interface so changing R to Q might tend to reduce V3 crown
solvent exposure and/or instability possibly involving proximal residues near to the C
strand, such as N197 or K121 (Fig. 10) (54, 58). Importantly, R315Q did not alter
neutralization properties of CM-LK relating to other bnAbs, except for a slight reduction
in MPN of CH01 (Fig. 9C; data not shown). Thus, the triple mutant, CM-LKQ, retained the
relative trimer stability of Comb-mut with added accessibility to V2 bnAbs and disrup-
tion of V3 crown epitopes at the apex of the trimer.
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HIV-1 Env trimer stability and heterogeneity can contribute to viral ﬁtness, the
former by ensuring prolonged infectivity and the latter by facilitating the evasion of
host antibodies. However, these properties of Env are also signiﬁcant variables in
vaccine design. Incomplete neutralization or shallow dose-response curves observed
with V2, V3, and CD4bs antibodies against the labile ADA isolate revealed heteroge-
neity in Env. We studied the relationship between Env functional stability and neutral-
ization by V2 and V3 antibodies among mutants of ADA and hyperstable Comb-mut
Env backgrounds. We found a positive correlation between Env stability and MPN of V2
bnAb PG9, as well as an inverse correlation between stability and sensitivity to V3
crown antibodies. In the process, we identiﬁed changes in Env that enhance neutral-
ization by V2 bnAbs, stabilize native trimers, and abrogate neutralization by V3 crown
antibodies. A relatively stable, homogeneous Env trimer is described that combines
these features (e.g., Comb-mut LKQ).
We identiﬁed 17 mutations (out of 36) throughout ADA within and outside V2 and
V3 that enhanced PG9 neutralization, 9 of which stabilized Env, and 17 that reduced V3
crown neutralization (Fig. 10). These stabilizing mutations (i.e., N136S, S143D, N302Y,
R315Q, A316T, F317W, T319A, L565M, Q567K, and T605P) might be useful in engineer-
ing other Env trimer immunogens considering that these positions are relatively
conserved. Some of the stabilizing mutations, e.g., N136S (V1), N302Y (V3), and L565M
FIG 9 V3 crown neutralization correlates inversely with trimer thermostability and PG9 neutralization
(MPN). (A) T90 values of mutants of ADA are plotted against the IC50 of V3 antibody 447-52D. A
statistically signiﬁcant relationship is seen between increased Env stability and a decrease in 447-52D
neutralization. (B) The IC50 of 447-52D is plotted against the MPN at 5 g/ml of PG9. Mutants in the V2
domain (between amino acids 160 and 190) that might directly affect PG9 binding were removed from
the analysis. (C) Neutralization of Comb-mut, CM-LK, and CM-LK R315Q pseudovirions by a panel of
antibodies shows that R315Q abrogates neutralization by V3 crown antibody 447-52D (middle panel)
without altering the neutralization properties of PG9 (top panel) and VRC01 (bottom panel). Data shown
are from a representative experiment performed in triplicate, and error bars represent the standard
deviations from the mean.
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(HR1), had arisen during escape from the CCR5 inhibitor, 5P12-RANTES (47), whereas
others, e.g., T605P (DSL) and A612S (HR2), had facilitated escape from the fusion
inhibitor PF-68742 (D. P. Leaman and M. B. Zwick, unpublished observations). Notably,
others have also reported on fusion inhibitor-escape mutations that were trimer
stabilizing (59, 60). Perhaps mutations that escape fusion inhibition are often trimer
stabilizing because they act to tighten subunit interfaces in order to restrict inhibitor
binding.
Recently, Herschhorn et al. identiﬁed a number of mutations in V1V2 that increased
sensitivity of HIV-1 to CD4 mimics, V3 MAbs, CD4i MAbs, weakly neutralizing CD4bs
MAbs, and cold inactivation, but decreased sensitivity to small-molecule inhibitors of
CD4-induced conformational changes, as well as to V2 and CD4bs bnAbs (52). Single-
molecule FRET analysis showed that these mutations caused Env to adopt a less stable,
more open conformation that the authors described as a local energy well (state 2) in
between unliganded Env (state 1) and fully CD4-bound Env (state 3). Beauparlant et al.
identiﬁed mutants of Env, including I165K and F317L, which showed increased infec-
tivity toward CD4-deﬁcient target cells and were also hyper-sensitive to CCR5 inhibitors,
V3, CD4i, and weak CD4bs Abs; these authors surmised that it was in a conformation
similar to the state 2 described by Herschhorn et al. (61). Most likely, the mutations that
we found which stabilized Env and decreased exposure of V3 are stabilizing state 1,
while mutations that did the opposite are destabilizing state 1, while favoring the
adoption of state 2. However, the activation barrier between states 1 and 2 might also
be affected, so to parse out the energetic states involved more detailed studies would
be needed.
How does increasing trimer stability reduce IC50s and improve the MPN of nAbs to
the V3 crown and V2 (N160), respectively? Mutations that increase trimer stability might
FIG 10 Location on Env of mutations that increase trimer stability or V2 neutralization. (A) Mutations that were found to increase PG9 neutralization or increase
trimer stability are indicated as spheres on the crystal structure of JRFL envelope (PDB 5FYK). In the inset images, key residues at positions 165 and 169 (B) and
position 315 (C) of gp120 are shown with residues nearby that may interact with them. Hydrogen bonds between neighboring amino acid residues, predicted
using PyMOL, are shown using red dashed lines. I165 and R315 are shown in both inset images for orientation.
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raise IC50s of V3 crown Abs by limiting the conformations and/or duration of V3 crown
exposure before it “reburies” in the trimer, thus lowering the on rate and narrowing the
range of antibody afﬁnities for the spike. We observed a correlation between Env
stability and the MPN (but not the IC50) of PG9. V2 bnAbs, including PG9, may recognize
a more stable conformation of the trimer than the V3 crown antibodies, so changes in
trimer stability may have less of an effect on the IC50s of V2 bnAbs. Mutations that
improve the MPNs of V2 bnAbs might relate to improved recognition of Env as it
becomes more uniformly glycosylated and folded, either in the unliganded state, the
asymmetric bnAb-bound state, or both of these states.
We found that neutralization by V2 bnAbs improved due to mutations I165L and
V169K. L165 is a contact residue in a complex between V2 peptide and PG9 (21) and
is also a “TD” mutation that has been shown to improve trimerization of soluble gp140s
(9). I165L might alter packing of V2 on the trimer to improve accommodation of V2
bnAb. K169 has been associated with decreased risk of infection in the RV144 clinical
trial (12, 62, 63). Antibodies were also isolated from RV144 vaccinees that bound to
K169 and, although they only neutralized Tier 1 viruses, were capable of mediating
ADCC against tier 2 isolates, which has suggested a mechanism for RV144 vaccine
protection (64). We found that V169K increased Env recognition and MPN by multiple
V2 bnAbs, which might be explained by the Lys side chain improving interactions with
anionic, Tyr-sulfated CDR H3s of these antibodies (16, 21). Notably, the MPN of PGT145
was decreased by V169K, so some heterogeneity in V2 must exist with this mutant,
perhaps due to interactions of K169 with surrounding glycosylation. PGT145 reportedly
binds in a “straight-up-and-down” orientation and makes contact with all three gp120
protomers, in contrast to the asymmetric approach of PG9-type V2 bnAbs, which could
make penetrating a stabilized trimer apex more difﬁcult (54). However, PGDM1400 is a
somatic variant of PGT145 that binds to the trimer in the same orientation as PGT145
(17), and its MPN is not reduced against CM-LK, so we speculate that the reduced
PGT145 neutralization is due to effects of local and residual glycan heterogeneity that
hinders PGT145 but that PGDM1400 can avoid. Virus containing a mixture of Comb-mut
and CM-LK—which individually showed either PG9 or PGT145 partial neutralization—
was 100% neutralized by a cocktail of the two antibodies, suggesting that glycosylation
sites from adjacent protomers were modiﬁed and recognized independently.
We showed that the thermostability of ADA was increased by blocking com-
plex glycosylation, e.g., using swainsonine, kifunensine, and GnTI/ cells. The
effects of glycosylation on protein stability can be difﬁcult to predict. However, increas-
ing glycosylation has boosted protein stability in other systems (65–67). Perhaps the
untrimmed mannose residues left by glycosylation inhibitors stabilize Env through
packing of the larger, more uniform mannose residues, or by reducing the favorability
of unfolding by altering the entropy of water in the hydration shell over exposed
hydrophobic protein patches similar to the mechanism by which polyethylene glycol
modiﬁcations improve thermostability of proteins (68, 69). Whatever the mechanism,
our results suggest that preventing the trimming of glycans may be a useful tool for
increasing the functional thermostability of membrane Env immunogens.
BN-PAGE analysis showed that Comb-mut-LK trimers were recognized more efﬁ-
ciently and by a greater number of V2 bnAbs than Comb-mut and that the bnAb-Env
association was improved further by chemical cross-linking. We note, too, that MPER
and gp41 interface bnAbs 10E8, PGT151, and 35O22 potently neutralize Comb-mut-
LKQ with high MPNs similar to those for Comb-mut (70), suggesting that this Env is
relatively homogeneous throughout the trimer interfaces.
Will Env trimer stabilization help in eliciting bnAb? No immunizations with soluble
trimers stable or otherwise have elicited signiﬁcant bnAb responses so additional
factors will most likely play a role (71, 72). Feng et al. showed recently that trimer
stability correlated with elicitation of autologous nAbs against a few Envs (73). Unstable
trimers are prone to shedding of gp120 (74), proteolysis (75) and antibody-mediated
destabilization (51, 76), which may limit B cell responses against quaternary bnAb
epitopes. Autologous nAbs have been associated with Envs that lack particular glycans
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(“glycan holes”) including JR-FL, BG505, and CAP257 that lack glycans at N197, N241,
and V5, respectively (77–79). Eliciting bnAbs may require B cells of speciﬁc germ line
origins (80) and high levels of somatic hypermutation (81). In order to better inform
strategies to elicit bnAbs (i.e., trigger relevant B cells, drive desired afﬁnity maturation,
and limit off-target responses), deﬁnition and control over Env trimer heterogeneity
and stability will likely become more important.
MATERIALS AND METHODS
Plasmids and cell lines. Reagents obtained through the NIH AIDS Reagent Program included
pSG3Δenv from J. Kappes and X. Wu (82), pLAI.2 from K. Peden (83), and TZM-bl cells from J. Kappes, X.
Wu, and Tranzyme, Inc. (84). Plasmids pcDNA-ADA, pcDNA-Comb-mut, pLAI-ADA, and pLAI-Comb-mut
were described previously (44). BG505 N332 env was synthesized using codon optimization and a tPA
leader (GeneWiz) and subcloned into the vector, pLentiIII (ABM, Canada). HEK-293T cells were purchased
from the American Type Culture Collection, and HEK-293S cells were kindly provided by H. G. Khorana
(MIT).
Antibodies and antibody production. IgGs b12, PG9, PG16, PGT128, PGT145, PGDM1400, F425-
B4e8, 2F5, VRC01, Z13e1, and 10E8 were produced in-house. Antibodies were produced starting with two
plasmid DNAs, one containing a heavy chain and a other light chain, which were transiently transfected
into 293F cells; IgG was puriﬁed from cell culture supernatant by protein A afﬁnity chromatography, as
previously described (85). For some early experiments, b12, PG9, PG16, PGT128, PGT145, and PGDM1400
were kindly provided by Dennis Burton (TSRI). CH01 was a gift from B. Haynes (Duke University), and
VRC26.08 was provided by J. Mascola (VRC). 4E10 and 2G12 were purchased from Polymun Scientiﬁc
(Austria). The antibodies 19b, 39F, and 17b were a gift from James Robinson (Tulane).
Env mutagenesis. Mutations were introduced into Env ADA and Comb-mut in pcDNA3.1 using a
QuikChange kit (Agilent) according to the protocol provided. Plasmids were DNA sequence veriﬁed,
transformed into NEB 5-alpha cells (New England BioLabs), and puriﬁed using a Maxiprep kit (Qiagen).
Key mutants of Env were subcloned into the pLAI plasmid to produce infectious molecular clone (IMC)
as previously described (86).
Virus production. Pseudotyped virus was produced using HEK-293T cells that were transiently
transfected with Env plasmid DNA, the HIV-1 backbone plasmid, pSG3ΔEnv (82) and 25K polyethylenei-
mine, as previously described (86). In some cases, kifunensine and swainsonine were added to cells 30
min prior to transfection at 25 and 20 M, respectively (4, 43). IMC was produced by the transient
transfection of HEK-293T cells using pLAI-ADA, pLAI-Comb-mut, and cognate mutants. Cell culture
supernatant was harvested 3 days posttransfection and centrifuged at 20,000 rpm to pellet the virus.
Virions were resuspended in 100 phosphate-buffered saline and frozen at 80°C.
Infectivity and neutralization assays. Viral infectivity and neutralization assays were performed as
described previously (86). Brieﬂy, TZM-bl cells were seeded onto a 96-well plate in 100 l of Dulbecco
modiﬁed Eagle medium supplemented with fetal bovine serum, penicillin, streptomycin, and glutamine.
Cells were incubated at 37°C for 24 h prior to addition of virus. Virus was coincubated with inhibitor at
37°C for 1 h prior to adding to TZM-bl cells. Virus neutralization was determined 48 h later by adding
Bright-Glo (Promega) and measuring luciferase activity using a Synergy H1 plate reader (BioTek).
HIV-1 Env stability-of-function assay. Thermostability (T90) assays were performed as described
previously (45). Brieﬂy, pseudotyped virus was incubated at temperatures from 37°C to 57°C for 1 h on
a Mastercycler PCR Gradient (Eppendorf). Virus aliquots were added to microwells containing TZM-bl
cells. Infectivity was determined as above and plotted as a function of temperature. T90 values were
interpolated as the temperature at which virus infectivity decreased by 90%.
BN-PAGE mobility shift and Western blotting. BN-PAGE mobility shift assays were performed as
previously described (43, 44, 75). To measure Env trimer stability, virions were subjected to a heat
gradient prior to electrophoresis. For gel mobility shift assays, IMCs were incubated with antibody at
room temperature for 30 min. In some cases virus was cross-linked using BS3 (Thermo) to prevent bound
antibody from dissociating during the gel run. Virus was solubilized with 1% DDM and loaded onto a 3
to 12% gradient NativePAGE Bis-Tris gel (Invitrogen). Proteins were transferred onto a polyvinylidene
diﬂuoride membrane (Bio-Rad), probed using a cocktail of antibodies to gp120 (b12, 2G12, and
F425-B4e8; 2 g/ml each) and gp41 (4E10, Z13e1, and 2F5; 1 g/ml each), and the blot was developed
using ECL Plus substrate (Life Technologies).
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